The TONMYA launch is gaining real traction with accelerating scripts and expanding payer coverage, but the cash burn rate ($84.6M in H1 2026) is elevated and implies a potential capital raise or dilutive financing before the end of 2027. Watch September 2026 sales force deployment for its effect on script growth and monitor any Form S-3 filing or equity offering as a negative catalyst.
Price Chart
Executive Summary
Tonix Pharmaceuticals reported Q2 2026 net product revenue of $13.5M, up from $2.0M a year ago, driven by $11.0M in TONMYA sales (197% QoQ growth). The cash position remains solid at $176.2M, but the net loss widened to $40.6M ($2.44 per share) as R&D and SG&A spending surged. The EPS miss vs. consensus for the prior quarter (-11.8%) and heavy cash burn rate are bearish offsets to the promising commercial ramp.
Key Financial Metrics
Key Facts
- TONMYA net sales $11.0M in Q2 2026, up 197% quarter-over-quarter
- Total net product revenue $13.5M vs $2.0M year ago, including $2.5M from legacy migraine products
- 12,592 total prescriptions for TONMYA, up 100% QoQ; new patient scripts up 36%; refills up 207%
- Payer coverage expanded to ~136M covered lives (43% of U.S.); expected to reach ~145M in Jan 2027
- Cash & cash equivalents $176.2M as of June 30, 2026 vs $207.6M at Dec 31, 2025
- Net cash used in operations $84.6M in H1 2026 (vs $31.4M in H1 2025)
- Sales force expanding to ~150 reps by September 2026
- First patient enrolled in Phase 2 HORIZON study of TNX-102 SL for MDD
- Phase 2 adaptive field study for TNX-4800 (Lyme disease prevention) on track for Q1 2027 start
- Subsequent to quarter-end, raised $3.7M via ATM facility
- Shares outstanding as of Aug 7, 2026: 17.15M
- Cash runway expected into early Q2 2027
Financial Impact
Net product revenue growth of $13.5M (+576% YoY) was partially offset by a $19.8M increase in SG&A and $8.6M increase in R&D; net loss widened to $40.6M vs $28.3M; cash burn rate $42.3M/quarter
Risk Factors
- Cash burn rate may require additional financing within 12 months despite current $176.2M cash
- EPS miss of -11.8% vs consensus for prior quarter signals pressure on bottom line
- Increased SG&A ($36M vs $16.2M) could compress operating leverage if TONMYA adoption slows
- Pipeline programs (TNX-102 SL, TNX-4800, TNX-1500) remain in early-to-mid-stage development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3341695 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | Press Release | $5.73 | awaiting T+20 | — | $5.30 (−7.50%) |
Oct 15, 2026 11d ago | 8-K | $6.42 | awaiting T+20 | — | $5.30 (−17.45%) |
Oct 2, 2026 24d ago | 8-K | $8.07 | awaiting T+20 | — | $5.30 (+34.32%) |
Sep 22, 2026 4w ago | 8-K | $10.59 $5.78 | ▼ −45.42% | ▼ −44.86% | $5.30 (−49.95%) |
Sep 8, 2026 6w ago | 8-K | $13.16 $7.70 | ▼ −41.49% | ▼ −43.46% | $5.30 (−59.73%) |
Aug 10, 2026 11w ago | 8-K | $12.59 $13.16 | ▲ +4.53% | ▲ +5.44% | $5.30 (−57.90%) |
Aug 10, 2026 11w ago | Press Release | $12.59 $13.16 | ▲ +4.53% | ▲ +5.44% | $5.30 (−57.90%) |
Aug 3, 2026 12w ago | 8-K | $10.67 $14.10 | ▲ +32.15% | ▲ +30.91% | $5.30 (−50.33%) |
Jul 27, 2026 13w ago | Press Release | $10.37 $12.45 | ▲ +20.06% | ▲ +16.76% | $5.30 (−48.89%) |
Jul 13, 2026 15w ago | 8-K | $11.71 $12.59 | ▲ +7.56% | ▲ +4.38% | $5.30 (−54.72%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers